TAIPEI, Taiwan, June 4 /Xinhua-PRNewswire/ -- TaiGen Biotechnology today announced that current board member, President and Chief Executive Officer, Dr. Ming Chu Hsu, has been unanimously elected as Chairman of the Company’s Board of Directors.
Dr. Hsu will assume the position of Chairman from Mr. Show Chung Ho, who will continue his role as a member of the Steering Committee and Director of the Board.
“Mr. Ho’s vision and support have been vital to TaiGen since its inception. We are all grateful for his past and continuing contributions,” said Dr. Hsu. “My role as CEO with TaiGen’s business and scientific teams has been extremely rewarding, and I welcome the Board’s support in its decision to expand my duties to the position of Chairman. It is a very exciting time for the company. I look forward to working with my colleagues and fellow board members as we push forward our development programs and business plan.”
Dr. Hsu founded TaiGen Biotechnology in 2001 as President and Chief Executive Officer, and has led TaiGen through a period of extraordinary growth. Dr. Hsu was the founding director of the Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes and Program Leader of the National Science and Technology Program in Biotech / Pharmaceutical Research in Taiwan. Before her return to Taiwan in 1998, Dr. Hsu was Research Director for Oncology and Virology at Hoffmann - La Roche USA.
About TaiGen Biotechnology Co., LTD
TaiGen Biotechnology ( www.taigenbiotech.com ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, diabetic complications and cancer for the worldwide market. TaiGen has a full capacity in new drug R&D and clinical development in China, Taiwan, US and other countries. Nemonoxacin, once-a-day oral and IV antibacterial active against MRSA, gram-positive and -negative pathogens, is currently in US phase 2 trials for community-acquired pneumonia and soon diabetes foot infection. The company has first-in-class phase 1-ready drug candidates for treating critical limb ischemia and retinopathy/age-related macular degeneracy, and advanced preclinical candidates for chronic Hepatitis C virus infection and cancer.
Contact Information: Stephen Ip, Ph.D. SVP Global Business Development Email: sip@taigenbiotech.com Tel: +886-2-2790-1861 Fax: +886-2-2790-9962 Add: 7F, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 11470, R.O.C.
TaiGen Biotechnology Co., LTD
CONTACT: Dr. Stephen Ip of TaiGen Biotechnology, +886-2-2790-1861, fax+886-2-2790-9962, sip@taigenbiotech.com
Web site: http://www.taigenbiotech.com/
